Nasdaq mrsn.

Find the latest Earnings Report Date for Mersana Therapeutics, Inc. Common Stock (MRSN) at Nasdaq.com.The average price point forecasted by analysts for Mersana Therapeutics Inc (MRSN) is $2.00, which is $0.59 above the current market price. The public float for MRSN is 86.99M, and currently, short sellers hold a 12.97% ratio of that float. The average trading volume of MRSN on November 15, 2023 was 2.15M shares. Top 5 AI Stocks to Buy for 2023.NASDAQ: Mersana Therapeutics Inc (MRSN) = 1.90 USD. Provided by Alpha Vantage. Mersana Therapeutics Inc stock (MRSN) in USD. 1 MRSN = 1.90 USD. 1 tháng. 6 tháng. 1 year. 5 năm. Hold over 40 currencies to convert and send money at any time. Open an account. Mersana Therapeutics Inc stock performance at a glance. Check Mersana …... headquartered in Cambridge, MA. Show more. ---. Top 5 ETFs holding MRSN. Name. Market Value. Smart Score. VTI. Vanguard Total Stock Market ETF. $4.06M. 8. IWV.

The latest price target for Marinus Pharma ( NASDAQ: MRNS) was reported by Truist Securities on Wednesday, November 8, 2023. The analyst firm set a price target for 25.00 expecting MRNS to rise to ...Mersana Therapeutics, Inc. Common Stock (MRSN) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Get the latest Nu Holdings Ltd (NU) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

In May, however, MRSN experienced a dramatic leap to $7 due to promising Ovarian Cancer data from ImmunoGen - a sphere where MRSN's key asset is active. Fueled by momentum and FOMO, MRSN's price ...The US Food and Drug Administration (FDA) handed out its first-ever approval for the treatment of postpartum depression (PPD) on Tuesday (March 19) to biopharmaceutical giant Sage Therapeutics ...

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...That number of contracts represents approximately 1.5 million underlying shares, working out to a sizeable 117.2% of MRSN's average daily trading volume over the past month, of 1.3 million shares.Największe straty zanotowała spłółka Mersana Therapeutics Inc (NASDAQ: MRSN), która była pod kreską 72,63%, zamykając sesję na poziomie 1,07. W końcówce handlu spółka Yellow Corp (NASDAQ: YELL) straciła 44,12% i zakończyła dzień notowań na poziomie 0,57, a spółka ABVC Biopharma Inc (NASDAQ: ABVC) wzrosła o 41,73% …Dec 4, 2023 · Citigroup upgraded its rating of Mersana Therapeutics MRSN to Buy with a price target of $5.00, changing its price target from $1.00 to $5.00. Shares of Mersana Therapeutics are trading up 5.26% ... Citigroup upgraded its rating of Mersana Therapeutics MRSN to Buy with a price target of $5.00, changing its price target from $1.00 to $5.00. Shares of Mersana Therapeutics are trading up 5.26% ...

Martin Huber. Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet …

CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Analyzing the MRSN fundamentals. Recent quarter sales for Mersana Therapeutics Inc [NASDAQ:MRSN] were 10.65 billion which represents 148.69% growth. In the same period, the company’s revenue per employee was $176,033, whereas its income per employee was -$1,352,397.The following insider purchased MRSN shares in the last 24 months: Andrew A F Hack ($9,646,046.46). How much insider buying is happening at Mersana Therapeutics? Insiders have purchased a total of 2,382,282 MRSN shares in the last 24 months for a total of $9,646,046.46 bought.CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Oct 31, 2023 · CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ... Mar 16, 2023 · On March 16, 2023, JP Morgan upgraded their outlook for Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Overweight.. Analyst Price Forecast Suggests 236.26% Upside. As of March 16, 2023, the ... CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Największe straty zanotowała spłółka Mersana Therapeutics Inc (NASDAQ: MRSN), która była pod kreską 72,63%, zamykając sesję na poziomie 1,07. W końcówce handlu spółka Yellow Corp (NASDAQ: YELL) straciła 44,12% i zakończyła dzień notowań na poziomie 0,57, a spółka ABVC Biopharma Inc (NASDAQ: ABVC) wzrosła o 41,73% …Mersana Therapeutics, Inc. Common Stock (MRSN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. NASDAQ: VIRX. $50,000,000. Term Loan. S. San Francisco, CA. NASDAQ: KZR. $100,000,000. Term Loan. Cambridge, MA. NASDAQ: MRSN. $50,000,000. Term Loan. Seattle, ...Find the latest SEC Filings data for Mersana Therapeutics, Inc. Common Stock (MRSN) at Nasdaq.com.Adc Therapeutics SA (ADCT) shares have gone down -62.70% during the last six months, with a year-to-date growth rate less than the industry average at -19.60% against 15.30. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -50.00% this quarter and then jump 33.80% in the quarter after that.

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...MRSN opened at $1.90 on Monday. The stock has a market cap of $229.10 million, a PE ratio of -1.07 and a beta of 1.39. The company has a quick ratio of 3.68, a current ratio of 3.68 and a debt-to ...

The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a clinical-stage biotechnology company that is involved in the research and development of antibody-drug conjugates for the treatment of cancer.CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Sep 20, 2022 · NasdaqGS:MRSN Earnings and Revenue Growth September 20th 2022 This free interactive report on Mersana Therapeutics' balance sheet strength is a great place to start, if you want to investigate the ... CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Martin Huber. Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech ...

Dec 4, 2023 · Citigroup upgraded its rating of Mersana Therapeutics MRSN to Buy with a price target of $5.00, changing its price target from $1.00 to $5.00. Shares of Mersana Therapeutics are trading up 5.26% ...

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN ), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

MRSN’s last price was a discount, traded about -520.65% off its 52-week high of $9.62. The share price had its 52-week low at $0.80, which suggests the last value was 48.39% up since then. When we look at Mersana Therapeutics Inc’s average trading volume, we note the 10-day average is 1.51 million shares, with the 3-month average coming to ...CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Jan 25, 2023 · Follow. CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline ... The latest price target for . Mersana Therapeutics (NASDAQ: MRSN) was reported by Citigroup on Friday, July 28, 2023.The analyst firm set a price target for 1.00 expecting …In May, however, MRSN experienced a dramatic leap to $7 due to promising Ovarian Cancer data from ImmunoGen - a sphere where MRSN's key asset is active. Fueled by momentum and FOMO, MRSN's price ...6.26%. $31.54M. AcelRx Pharmaceuticals Inc. 2.87%. $11.12M. MRNS | Complete Marinus Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full ...Find the latest SEC Filings data for Mersana Therapeutics, Inc. Common Stock (MRSN) at Nasdaq.com.Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary endpoint.RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today ...September 30, 2020 December 31, 2019 Cash, cash equivalents and marketable securities $ 270,936 $ 99,790: Working capital (1): 253,864 77,256Mersana Therapeutics, Inc. (MRSN) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 1.6500 +0.0600 (+3.77%) At close: 04:00PM EST 1.7500 +0.10 (+6.06%) After hours: 07:30PM...

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...Follow. CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline ...Instagram:https://instagram. frieght wavesdental insurance no yearly maximumwpc dividendfidelity investments news MRSN’s last price was a discount, traded about -520.65% off its 52-week high of $9.62. The share price had its 52-week low at $0.80, which suggests the last value was 48.39% up since then. When we look at Mersana Therapeutics Inc’s average trading volume, we note the 10-day average is 1.51 million shares, with the 3-month average coming to ... gabxxsocial security and government shutdown Mersana Therapeutics, Inc. Common Stock (MRSN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Mersana Therapeutics Inc (NASDAQ:MRSN) trade information. Sporting 12.80% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 11/14/23 when the MRSN stock price touched $1.41 or saw a rise of 1.4%. largest prop trading firms Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 …Mersana Therapeutics Inc (NASDAQ:MRSN)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 1.31. At the close of trading, the stock’s price was $1.55, to imply an increase of 3.68% or $0.05 in intraday trading. The MRSN share’s 52-week high ...Jul 13, 2021 · Mersana Therapeutics, Inc. (NASDAQ: MRSN) was in 25 hedge funds' portfolios at the end of March. The all time high for this statistic is 30. Our calculations also showed that MRSN isn't among the ...